MedTrace Logo

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

NCT01783197 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2023-08-04

No results posted yet for this study

Summary

This research is being done because further research on selumetinib in combination with standard chemotherapy treatment is needed. Although the number of treatment options for patients with advanced non-small cell lung cancer has increased over the past decade, prognosis remains poor, and there is a need for additional therapeutic options.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Paclitaxel

DRUG

Carboplatin

DRUG

Selumetinib

DRUG

Pemetrexed

DRUG

Cisplatin

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Garth Nicholas · Ottawa Health Research Institute - General Division

  • John Goffin · Juravinski Cancer Centre at Hamilton Health Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-04
Primary Completion
2017-04-18
Completion
2019-04-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01783197 on ClinicalTrials.gov